CAMBRIDGE, Mass. (AP) _ Blueprint Medicines Corp. (BPMC) on Thursday reported a loss of $123.5 million in its second quarter.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $2.28.
The results missed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of $2.08 per share.
The cancer drug developer posted revenue of $8.3 million in the period, exceeding Street forecasts. Seven analysts surveyed by Zacks expected $7.6 million.
Blueprint Medicines shares have fallen roughly 8% since the beginning of the year. The stock has declined 25% in the last 12 months.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BPMC at https://www.zacks.com/ap/BPMC
Please read our comment policy before commenting.